Clinical Trials
5
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Phase 1
Recruiting
- Conditions
- Recurrent World Health Organization (WHO) Grade II GliomaWHO Grade II GliomaRecurrent WHO Grade III GliomaWHO Grade III Glioma
- Interventions
- Procedure: Magnetic Resonance ImagingProcedure: Magnetic Resonance Spectroscopic Imaging
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Susan Chang
- Target Recruit Count
- 300
- Registration Number
- NCT04540107
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Phase 1
Active, not recruiting
- Conditions
- Glioblastoma Multiforme (GBM)
- Interventions
- Drug: Hyperpolarized 13C Pyruvate
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Susan Chang
- Target Recruit Count
- 17
- Registration Number
- NCT04019002
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Phase 1
Recruiting
- Conditions
- Glioma
- Interventions
- Radiation: Hyperpolarized Carbon C 13 PyruvateProcedure: Magnetic Resonance ImagingRadiation: Radiation TherapyDrug: Chemotherapy
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Susan Chang
- Target Recruit Count
- 140
- Registration Number
- NCT03739411
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
68Ga-citrate PET/MR Imaging for Glioma
Terminated
- Conditions
- Glioma
- Interventions
- Drug: 68Ga-citrate PET/MR
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Susan Chang
- Target Recruit Count
- 2
- Registration Number
- NCT03335280
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Phase 2
Completed
- Conditions
- Adult Subependymal Giant Cell AstrocytomaAdult Diffuse AstrocytomaAdult Mixed GliomaAdult OligodendrogliomaRecurrent Adult Brain Neoplasm
- Interventions
- Other: Archival Tissue Analysis
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Susan Chang
- Target Recruit Count
- 58
- Registration Number
- NCT00823459
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
News
No news found